Viruses, Vol. 15, Pages 1148: Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs

Viruses, Vol. 15, Pages 1148: Novel Adjuvant S-540956 Targets Lymph Nodes and Reduces Genital Recurrences and Vaginal Shedding of HSV-2 DNA When Administered with HSV-2 Glycoprotein D as a Therapeutic Vaccine in Guinea Pigs Viruses doi: 10.3390/v15051148 Authors: Sita Awasthi Motoyasu Onishi John M. Lubinski Bernard T. Fowler Alexis M. Naughton Lauren M. Hook Kevin P. Egan Masaki Hagiwara Seiki Shirai Akiho Sakai Takayuki Nakagawa Kumiko Goto Osamu Yoshida Alisa J. Stephens Grace Choi Gary H. Cohen Kazufumi Katayama Harvey M. Friedman Herpes simplex virus type 2 (HSV-2) is a leading cause of genital ulcer disease and a major risk factor for acquisition and transmission of HIV. Frequent recurrent genital lesions and concerns about transmitting infection to intimate partners affect the quality of life of infected individuals. Therapeutic vaccines are urgently needed to reduce the frequency of genital lesions and transmission. S-540956 is a novel vaccine adjuvant that contains CpG oligonucleotide ODN2006 annealed to its complementary sequence and conjugated to a lipid that targets the adjuvant to lymph nodes. Our primary goal was to compare S-540956 administered with HSV-2 glycoprotein D (gD2) with no treatment in a guinea pig model of recurrent genital herpes (studies 1 and 2). Our secondary goals were to compare S-540956 with oligonucleotide ODN2006 (study1) or glucopyranosyl lipid A in a stable oil-in-water nano-emulsion (GLA-SE) (stu...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research